Results 141 to 150 of about 6,454 (219)

Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide

Journal of Diabetes, Volume 18, Issue 2, February 2026.
Network meta‐analysis comparing the effects of tirzepatide, semaglutide, and placebo on body weight reduction and glycemic outcomes in adults with overweight or obesity. ABSTRACT Introduction Pharmacological therapies are recommended for individuals with obesity.
Julia C. Bernardi, Deivyd V. S. Cavalcante, Ramon Huntermann, Maria E. Molinari, Luana Z. Zanon, Jacinthe Khater, Victor A. Gomez, Caroline O. Fischer‐Bacca   +7 more
wiley   +1 more source

A Review of the Management of Obesity in Primary Care

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT This review highlights the important role primary care plays in obesity management, using England as an example. It includes a comprehensive summary of current management and referral options for primary care clinicians, a discussion of the most up‐to‐date clinical guidelines for the use of GLP‐1 receptor agonists in England, and the evolving ...
H. M. Parretti, S. E. Erskine, K. D. Coulman, R. Mears, K. Clare, K. Williamson, R. Watkins, C. A. Hughes   +7 more
wiley   +1 more source

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review [PDF]

Introduction Obesity is a complex, multifactorial condition characterized by an excessive accumulation of body fat. It is widely recognized as a major public health issue due to its strong association with numerous chronic diseases. [1][2] The use of GLP-
Baran, Karolina, Blecharz, Gabriela, Jankowska, Marlena, Jańczyk, Natalia, Machalica, Jan, Mędrysa, Karolina, Pokrzepa, Jakub, Presak, Michał, Szwech, Julia, Winkowska, Alicja   +9 more
core   +1 more source

Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information‐Based Mapping Exercises Across the 42 Integrated Care Boards of England

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT Obesity medications are recommended in England with legislation necessitating their availability. However, given the number of people who meet clinically approved eligibility criteria, funding these medications and associated support services may limit efficacy at a population health level.
Anne de Bray, Hanna Schnitzer, Elisabeth Mahase, Puspha Singh, Rob Andrews, Barbara M. McGowan, Sarah Le Brocq, John P. H. Wilding, Stuart W. Flint, Jonathan M. Hazlehurst   +9 more
wiley   +1 more source

Changes in Eating Behaviour During Treatment With Obesity Medications

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT Obesity is a chronic, relapsing disease influenced by biological, environmental and behavioural factors. Pharmacological therapies have demonstrated substantial effects in weight loss, appetite suppression and modulation of food‐related thoughts; however, the long‐term effects of medications and eating behaviours across treatment phases ...
Ming Chuen Chong, Tak Ying Louise Ko, Philippus L. le Roux, Carel W. le Roux   +3 more
wiley   +1 more source

Associations of modifiable preconception, pregnancy and postpartum factors with health outcomes for women with type 2 diabetes and their children: A systematic review and meta‐analysis of observational studies

Diabetic Medicine, Volume 43, Issue 2, February 2026.
Abstract Aim Type 2 diabetes (T2D) in pregnancy is increasingly common and associated with suboptimal outcomes for these women and their children. We aimed to synthesize observational evidence on associations of modifiable preconception, pregnancy and postpartum risk factors with perinatal outcomes among women with pregestational T2D.
Danielle Schoenaker, Eleanor Dyer, Nicola Heslehurst, Grainne Kent, Sowmiya Gunabalasingam, Lily Hopkins, Artemis Kyrka, Rivka Lebrett, Angela C. Flynn, Sara L. White, Claire L. Meek, Rita Forde   +11 more
wiley   +1 more source

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 803-816, February 2026.
Abstract Treatment with GLP‐1 receptor agonists (GLP‐1 RAs) is effective in reducing body weight in individuals with overweight and type 2 diabetes (T2D). However, measurements indicate that a considerable portion of the weight loss derives from fat‐free mass (FFM), including skeletal muscle, which may compromise metabolic health and physical function.
Viktor Aimelet, Jens Juul Holst
wiley   +1 more source

Process for the preparation of Tirzepatide [PDF]

Title of the invention: Process for the preparation of Tirzepatide The present invention relates to a process for the preparation of Tirzepatide represented by the following structural formula-1. Formula-
, Srinivasan Thirumalai Rajan, Ghojala Venkat Reddy, Mallepally Venkat Reddy, Suryapeta Srinivas, Nidadavolu Chandrasekhar, MSN Laboratories Private Limited, R&D Center, Hyderabad, India.
core   +1 more source

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source